These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23425099)

  • 1. The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target.
    Gaffney DC; Soyer HP; Simpson F
    Australas J Dermatol; 2014 Feb; 55(1):24-34. PubMed ID: 23425099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
    Eder J; Simonitsch-Klupp I; Trautinger F
    Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic treatment options for advanced epithelial skin cancer.
    Soura E; Chasapi V; Stratigos AJ
    Expert Opin Pharmacother; 2015; 16(10):1479-93. PubMed ID: 26027692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor as a target for chemotherapy.
    Vallbohmer D; Lenz HJ
    Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S19-27. PubMed ID: 15871762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of targeted therapy in the treatment of squamous cell head and neck cancer].
    Gyergyay F
    Magy Onkol; 2007; 51(2):155-7. PubMed ID: 17660872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the epidermal growth factor receptor in colorectal carcinoma.
    Kurtin SE
    Cancer Nurs; 2007; 30(4 Suppl 1):S1-9. PubMed ID: 17666985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
    Karamouzis MV; Grandis JR; Argiris A
    JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor targeted therapies for solid tumours.
    Van den Eynde M; Baurain JF; Mazzeo F; Machiels JP
    Acta Clin Belg; 2011; 66(1):10-7. PubMed ID: 21485758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab in non-melanoma skin cancer.
    Wollina U
    Expert Opin Biol Ther; 2012 Jul; 12(7):949-56. PubMed ID: 22519406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update of cetuximab for non-melanoma skin cancer.
    Wollina U
    Expert Opin Biol Ther; 2014 Feb; 14(2):271-6. PubMed ID: 24387664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Targeting of epidermal growth factor receptor and applications in ORL cancer].
    Tortochaux J; Aunoble B; Rolhion C; Bourhis J
    Bull Cancer; 2003 Nov; 90 Spec No():S220-7. PubMed ID: 14763143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
    Rudnick EW; Thareja S; Cherpelis B
    Int J Dermatol; 2016 Mar; 55(3):249-58; quiz 256, 258. PubMed ID: 26566923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
    Cohen RB
    Clin Colorectal Cancer; 2003 Feb; 2(4):246-51. PubMed ID: 12620146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of cetuximab and panitumumab in oral squamous cell carcinoma cell lines: prognostic value of MAGE-A subgroups for treatment success.
    Hartmann S; Kriegebaum U; Küchler N; Lessner G; Brands RC; Linz C; Schneider T; Kübler AC; Müller-Richter UD
    J Craniomaxillofac Surg; 2013 Oct; 41(7):623-9. PubMed ID: 23375534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Zibelman M; Mehra R
    Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cutaneous side effects of EGFR inhibitors--appearance and management].
    Wollenberg A; Kroth J; Hauschild A; Dirschka T
    Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.